Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing Journal Article
| Authors: | Frampton, G. M.; Fichtenholtz, A.; Otto, G. A.; Wang, K.; Downing, S. R.; He, J.; Schnall-Levin, M.; White, J.; Sanford, E. M.; An, P.; Sun, J.; Juhn, F.; Brennan, K.; Iwanik, K.; Maillet, A.; Buell, J.; White, E.; Zhao, M.; Balasubramanian, S.; Terzic, S.; Richards, T.; Banning, V.; Garcia, L.; Mahoney, K.; Zwirko, Z.; Donahue, A.; Beltran, H.; Mosquera, J. M.; Rubin, M. A.; Dogan, S.; Hedvat, C. V.; Berger, M. F.; Pusztai, L.; Lechner, M.; Boshoff, C.; Jarosz, M.; Vietz, C.; Parker, A.; Miller, V. A.; Ross, J. S.; Curran, J.; Cronin, M. T.; Stephens, P. J.; Lipson, D.; Yelensky, R. |
| Article Title: | Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing |
| Abstract: | As more clinically relevant cancer genes are identified, comprehensive diagnostic approaches are needed to match patients to therapies, raising the challenge of optimization and analytical validation of assays that interrogate millions of bases of cancer genomes altered by multiple mechanisms. Here we describe a test based on massively parallel DNA sequencing to characterize base substitutions, short insertions and deletions (indels), copy number alterations and selected fusions across 287 cancer-related genes from routine formalin-fixed and paraffin-embedded (FFPE) clinical specimens. We implemented a practical validation strategy with reference samples of pooled cell lines that model key determinants of accuracy, including mutant allele frequency, indel length and amplitude of copy change. Test sensitivity achieved was 95-99% across alteration types, with high specificity (positive predictive value >99%). We confirmed accuracy using 249 FFPE cancer specimens characterized by established assays. Application of the test to 2,221 clinical cases revealed clinically actionable alterations in 76% of tumors, three times the number of actionable alterations detected by current diagnostic tests. © 2013 Nature America, Inc. |
| Journal Title: | Nature Biotechnology |
| Volume: | 31 |
| Issue: | 11 |
| ISSN: | 1087-0156 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2013-11-01 |
| Start Page: | 1023 |
| End Page: | 1031 |
| Language: | English |
| DOI: | 10.1038/nbt.2696 |
| PROVIDER: | scopus |
| PUBMED: | 24142049 |
| PMCID: | PMC5710001 |
| DOI/URL: | |
| Notes: | --- - Cited By (since 1996):1 - "Export Date: 2 December 2013" - "CODEN: NABIF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work